CRL vs ICLR: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
CRL and ICLR are similarly sized, but ICLR trades noticeably cheaper on forward earnings (13.80x vs 18.86x): the market is paying up for CRL's profile and pricing ICLR more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
CRL vs ICLR: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CRL | ICLR | What it tells you |
|---|---|---|---|
| Forward P/E | 18.86 | 13.80 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.40 | 1.22 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 90% of range | 71% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.81 | 1.35 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ICLR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CRL and ICLR affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRL and ICLR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRL and ICLR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Charles River Laboratories International (CRL) do?
Charles River Laboratories International, Inc. is a leading global contract research organization that helps pharmaceutical and biotech companies discover, develop, and safely test new drugs. It runs three reporting segments: Research Models and Services (RMS), which breeds and supplies purpose-bred lab animals and related services; Discovery and Safety Assessment (DSA), its largest segment, which runs toxicology and safety-testing studies that drugs must pass before human trials; and Manufacturing Solutions, which provides quality-control testing for biologics, cell and gene therapies, and other products. Charles River says it has supported a large majority of the drugs approved by the FDA in recent years, which underlines how embedded it is in the industry's R&D pipeline.
What does ICON plc (ICLR) do?
ICON plc (NASDAQ: ICLR) is a Dublin-headquartered contract research organization that provides outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government clients. As of March 2026 it had roughly 40,350 employees across about 97 locations in 55 countries, and it manages studies spanning compound selection through Phase I to Phase IV trials. Revenue is booked against a large backlog, so bookings and book-to-bill ratios are watched as closely as reported sales.
CRL vs ICLR: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CRL drivers: Biopharma R&D demand recovery; Activist-driven strategic review.
- ICLR drivers: Backlog and bookings momentum; Structural CRO outsourcing growth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending. For ICLR, iCON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion.
CRL or ICLR: which should you pick?
CRL vs ICLR: the full fundamentals
CRL. All figures here are approximate and tied to the asOf date; verify live numbers on a current quote page or the latest SEC filing before acting. CRL is a services company, so its value depends on biopharma R&D demand, execution on cost savings, and the outcome of the strategic review, not on any single commodity price. Valuation multiples are more meaningful here than for a cyclical producer, but they still swing with where the demand cycle sits.
ICLR. ICON reaffirmed full-year 2026 guidance of roughly $7.85 billion to $8.15 billion in revenue and about $10.00 to $11.00 in adjusted diluted EPS. The low-teens trailing multiple reflects softer near-term margins and demand, while backlog of around $22.7 billion underpins forward visibility. Figures are approximate and drawn from company filings and market data.
Headline figures (approximate, Jul 2026): CRL shows revenue trend Roughly flat to slightly up recently, with quarterly revenue around the $1 billion mark; annual revenue in the multi-billion range. Figures are approximate, verify live., profitability Profitable on an adjusted basis; GAAP earnings have been pressured by soft DSA demand and restructuring, with a cost-savings program aimed at protecting margins., balance sheet Carries acquisition-related debt; management has prioritized deleveraging and disciplined capital allocation. Confirm current leverage on the latest filing., market cap tier Mid-cap. Approximate figure has been in the several-billion-dollar range, well below its historical peak. Verify the live number.; ICLR shows market cap ~$8.9B, revenue (ttm) ~$8.1B, q1 2026 revenue ~$2.03B, q1 2026 adjusted eps ~$2.50.
The bottom line: CRL vs ICLR
CRL and ICLR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRL and ICLR exposure against your real portfolio. It is not an investment adviser.
Wondering how CRL or ICLR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Charles River Laboratories International with AI
Connect the broker you already use and ask Walnut's AI how CRL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CRL and ICLR?
+
Charles River Laboratories International, Inc. ICON plc (NASDAQ: ICLR) is a Dublin-headquartered contract research organization that provides outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government clients. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CRL or ICLR the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CRL or ICLR?
+
On forward P/E (as of August 2026), CRL trades at 18.86x and ICLR at 13.80x, so ICLR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CRL and ICLR?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CRL vs ICLR?
+
CRL: The central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending. Client concentration and the lumpiness of large study bookings add volatility to any given quarter. The activist strategic review is a double-edged sword: it could unlock value, but the outcome, timing, and any divestitures are uncertain and may disappoint. Regulatory and reputational scrutiny around animal research, plus a long-term industry shift toward non-animal testing methods, could pressure the RMS segment over time. The company also carries debt from past acquisitions, so a prolonged demand slump would weigh on cash flow and flexibility. Competition from other large CROs on price and capacity is persistent. ICLR: ICON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion. Margin pressure has been acute, with adjusted EBITDA margin falling to about 15.6% in Q1 2026 from the high-teens to roughly 20% range previously. Concentration among a handful of Top 10 pharma clients means mergers or pipeline cuts at a few customers can materially affect revenue. The company disclosed an internal accounting investigation and potential restatements, which prompted at least one analyst downgrade and adds uncertainty until resolved. Full-year 2026 revenue guidance of roughly $7.85 billion to $8.15 billion sits below 2025 levels, reflecting both a divestiture and organic softness.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CRL or ICLR; figures are approximate and dated (as of August 2026). Verify current data before investing.